

## Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

**Kimberley Hanson<sup>1</sup>, Stephen D. Robinson<sup>1</sup>, Karamallah Al-Yousuf<sup>2,3</sup>, Adam E. Hendry<sup>1</sup>, Darren W. Sexton<sup>4,5</sup>, Victoria Sherwood<sup>2,3</sup> and Grant N. Wheeler<sup>1</sup>**

<sup>1</sup> School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

<sup>2</sup> School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

<sup>3</sup> Present address: Division of Cancer Sciences, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK

<sup>4</sup> Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

<sup>5</sup> Present address: Pharmacy and Biomedical Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK

**Published:** November 27, 2018

**Copyright:** Hanson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The correct Author name is given below:

**Stephen D. Robinson**

Original article: Oncotarget. 2018; 9:3815-3829. <https://doi.org/10.18632/oncotarget.23378>